
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SKNY-1
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Recipient : SKNY Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals
Details : The acquisition of SKNY strategically positions MIRA to enter two high-growth pharmaceutical markets with a differentiated, next-generation oral therapy, SKNY-1, in preclinical development.
Product Name : SKNY-1
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 30, 2025
Lead Product(s) : SKNY-1
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Recipient : SKNY Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ketamine Analog
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharma Shows Ketamir-2 Restores Normalized Behavior in PTSD Animal Study
Details : Ketamir-2 is a proprietary, orally bioavailable new molecular entity that selectively targets the NMDA receptor, being investigated for the treatment of PTSD.
Product Name : Ketamir-2
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 16, 2025
Lead Product(s) : Ketamine Analog
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SKNY-1
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : SKNY Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals
Details : The acquisition of SKNY strategically positions MIRA to enter two high-growth pharmaceutical markets with a differentiated, next-generation oral therapy, SKNY-1, in preclinical development.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 12, 2025
Lead Product(s) : SKNY-1
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : SKNY Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ketamine Analog
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears IND For MIRA’s Ketamir-2 In Neuropathic Pain Trials
Details : Ketamir-2 is a novel oral NMDA receptor antagonist, being investigated for the treatment of neuropathic pain.
Product Name : Ketamir-2
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 29, 2025
Lead Product(s) : Ketamine Analog
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

MIRA Reports No Brain Toxicity for Ketamir-2 in FDA-Required Study
Details : Ketamir-2 is a novel oral ketamine analog, a NMDA receptor antagonist, being investigated for Neuropathic Pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ketamine Analog
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Shows Positive Ketamir-2 Data in Diabetic Neuropathy Animal Study
Details : Ketamir-2 is a non-opioid alternative, an oral ketamine analog, currently is being validated in animal model for diabetic neuropathy.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Ketamine Analog
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Starts Phase 1 Trial for Ketamir-2 in Neuropathic Pain
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 04, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharmaceuticals Submits IND for Ketamir-2, a Milestone in Company’s Development
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Pharmaceuticals Validates Ketamir-2 Safety for IND Submission
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 20, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
